HIFU IN BANGALORE, INDIA!

Innovative Prostate Cancer Treatment Introduced In Bangalore, India
High intensity focused ultrasound technology with the Sonablate® 500 medical device now available for patients through HealthCare Global Enterprises Ltd. (HCG)

CHARLOTTE, N.C., August 11, 2010—USHIFU, LLC (“US HIFU”), a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (“HIFU”) technologies, and its affiliate India High Intensity Focused Ultrasound Devices Private Limited (“India HIFU”), announce the introduction of Sonablate® HIFU technology for prostate cancer in Bangalore, India at several HealthCare Global Enterprises Ltd. (“HCG”) centers.
Dr. Raghunath S.K., the first urologist in Bangalore to treat prostate cancer using HIFU, treated the city’s first patient today at Bangalore Institute of Oncology, one of the HCG centers to offer Sonablate HIFU.
Sonablate HIFU is a minimally invasive, targeted approach to treating prostate disease with precision-focused ultrasound energy that, when delivered, raises the temperature of the tissue in a matter of seconds. The extreme, rapid-firing heat destroys the tissue at a specific target, known as a lesion, which measures 12x3x3 mm, approximately the size of a grain of rice. Lesions are created throughout the prostate that result in its destruction.

“We are thrilled with this new association with HCG and what it means for prostate cancer patients in India,” said Alex Gonzalez, US HIFU’s vice president of international operations. “Since HCG has 18 cancer care centers across Southeast Asia and India, more men facing prostate cancer will learn about and gain access to the technology through their network.”

Bangalore Institute is the fifth facility in India to offer Sonablate HIFU for men with localized prostate cancer. The first Sonablate HIFU services were introduced in December 2008 in Hyderabad; other cities to subsequently offer the treatment include New Delhi and Mumbai. More than 50 prostate cancer patients have been treated with Sonablate HIFU since its introduction.

“It has been our goal to partner with the finest hospitals in India in order for exponentially more men to gain easier access to the treatment.” said Mukesh Rana, country manager, India HIFU. “We knew there was a need for HIFU in this area because a few Bangalore residents recently traveled more than 2,000 kilometers to New Delhi for treatment.”
# # #


About USHIFU, LLC
USHIFU, LLC (US HIFU), a privately held healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. US HIFU manufactures the Sonablate® 500 medical device and is focused currently on treating primary and recurrent prostate cancer using Sonablate® HIFU. The company is engaged in ongoing research for technological advancements for the Sonablate® system or other ultrasound applications. US HIFU was founded in 2004 and is headquartered in Charlotte, N.C. Additional information can be found at www.ushifu.com.

About India HIFU
India High Intensity Focused Ultrasound Devices Private Limited (India HIFU) is an affiliate of US HIFU. India HIFU sells, markets and services Sonablate® HIFU devices for HIFU treatment of prostate cancer as well as develops new Sonablate® HIFU centers throughout India. Additional information can be found at www.india-hifu.com.

About the Sonablate® 500
The Sonablate® 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by Focus Surgery, Inc. Takai Hospital Supply Ltd. distributes the Sonablate® 500 in Southeast Asia. The Sonablate® 500 is not approved for use in the U.S. The Sonablate® 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate® 500 for the treatment of prostate cancer.